Journal: Nature Communications
Article Title: AAV-delivered muscone-induced transgene system for treating chronic diseases in mice via inhalation
doi: 10.1038/s41467-024-45383-z
Figure Lengend Snippet: a Schematic representing the genetic configuration of the AAV vector used for AAV MUSE iteration. b Schematic representation of the experimental procedure for AAV MUSE -mediated transgene expression in mouse lungs. c AAV MUSE -mediated luciferase expression for 20 weeks in mouse lungs. Eight-week-old female BALB/c mice were transduced with an AAV MUSE iteration comprising AAV2/lung-pWX126 (ITR-P SV40 -MOR215-1-pA-ITR, 5 × 10 11 vg) and AAV2/6-pWX342 (ITR-P SV40 -RTP1S::pA-luciferase-P CRE -ITR, 5 × 10 11 vg) via tail vein. Two weeks after the AAV injection, AAV MUSE -transduced mice were exposed to nebulized muscone for 4 h once every six weeks or exposed to a vehicle (a mixture of castor oil and ddH 2 O), and bioluminescence imaging was performed using an in vivo imaging system every 6 weeks. d Quantification of luciferase expression in the lung based on the bioluminescence IVIS imaging shown in ( c ). Data in ( d ) are presented as means ± SEM ( n = 4 mice). ** P < 0.01, *** P < 0.001. P values were obtained from two-tailed unpaired t tests. Source data are provided as a file.
Article Snippet: AAV (serotype 2/6) carrying pWX342 (ITR-P SV40 -RTP1S::pA-luciferase-P CRE -ITR) or pWX345 (ITR-P SV40 -RTP1S::pA-ΔmIL-4-P CRE -ITR) and AAV (serotype 2/lung) carrying pWX126, pWX127, or pWX158 were produced by Shanghai OBiO Technology.
Techniques: Plasmid Preparation, Expressing, Luciferase, Transduction, Injection, Imaging, In Vivo Imaging, Two Tailed Test
